MASH

Gilead gives up on $15M MASH bet with Yuhan after mulling preclinical data
Fierce Biotech
Fri, 10/11/24 - 11:14 am
Gilead Sciences
Yuhan
MASH
How Madrigal plans to win on the market with the first MASH drug
Pharma Voice
Thu, 10/10/24 - 09:51 am
Madrigal Pharmaceuticals
MASH
Rezdiffra
Lilly, Insitro Ink Unique AI Deal, Eye Novel Treatments for Metabolic Diseases
BioSpace
Wed, 10/9/24 - 09:46 am
Insitro
Eli Lilly
siRNA
MASH
Boehringer kickstarts two Phase III trials as MASH therapy wins breakthrough status
Clinical Trials Arena
Tue, 10/8/24 - 09:56 am
Boehringer Ingelheim
MASH
clinical trials
survodutide
Madrigal's Rezdiffra off to strong start, but 'bumpiness' is coming: analyst
Fierce Pharma
Thu, 08/8/24 - 11:15 am
Madrigal Pharmaceuticals
Rezdiffra
MASH
Boehringer, Lilly face off in MASH at EASL
Pharmaphorum
Mon, 06/10/24 - 11:14 am
Eli Lilly
Boehringer Ingelheim
MASH
EASL
tirzepatide
survodutide
Boehringer, Zealand Heat Up MASH Race With Strong Phase II Data
BioSpace
Fri, 06/7/24 - 11:17 am
Boehinger Ingelheim
Zealand Pharma
survodutide
MASH
NASH
Boehringer, Zealand’s GLP-1 MASH Data ‘Unintentionally’ Published by Medical Congress Website
BioSpace
Thu, 06/6/24 - 11:48 am
Zealand Pharma
Boehringer Ingelheim
MASH
survodutide
clinical trials
Lilly’s Tirzepatide Shows Positive Phase II NASH Data, Tees Up Potential Expansion
BioSpace
Wed, 06/5/24 - 11:08 am
Eli Lilly
NASH
MASH
clinical trials
tirzepatide
Viking's MASH drug scored where Madrigal's didn't, but shares fall on lack of direction
Fierce Biotech
Tue, 06/4/24 - 11:31 pm
Viking Therapeutics
MASH
VK2809
clinical trials vaccines
After two Big Pharma deals, Nimbus looks to keep the hits coming
Pharma Voice
Mon, 06/3/24 - 12:01 pm
Nimbus Therapeutics
Gilead Sciences
MASH
Takeda
89bio CMO touts advantages of pegozafermin following Phase III initiation
Clinical Trials Arena
Thu, 05/23/24 - 11:22 am
89Bio
pegozafermin
MASH
NASH
clinical trials
‘Remarkable interest’: Madrigal touts early launch progress for first MASH drug Rezdiffra despite VA hurdle
Fierce Pharma
Tue, 05/7/24 - 06:28 pm
Madrigal Pharmaceuticals
Rezdiffra
MASH
NASH
Novo Nordisk doses first subject in Phase I trial of NLRP3 inhibitor
Clinical Trials Arena
Mon, 05/6/24 - 11:38 am
Novo Nordisk
NLRP3 inhibitors
NNC6022-0001
VENT-01
clinical trials
MASH
NASH
chronic kidney disease
Boehringer signs $1.3B deal with RNA biotech Ochre Bio to team up against MASH
Fierce Biotech
Mon, 04/22/24 - 11:44 am
Boehringer Ingelheim
Ochre Bio
RNA
MASH
NASH
5 Promising MASH Therapies That Could Follow Madrigal’s Rezdiffra
BioSpace
Mon, 04/15/24 - 11:24 am
MASH
NASH
Madrigal Pharmaceuticals
Rezdiffra
Ionis Pharmaceuticals
ION224
Altimmune
pemvidutid
89Bio
pegozafermin
Viking Therapeutics
VK2809
Aligos Therapeutics
ALG-055009
D&D Pharmatech Granted Fast Track Designation from US FDA for DD01 for the Treatment of NASH/MASH
BioSpace
Tue, 04/2/24 - 11:37 am
D&D Pharmatech
DD01
MASH
NASH
FDA
fast track
89bio wins EMA priority status for MASH candidate pegozafermin
Clinical Trials Arena
Thu, 03/28/24 - 11:21 am
89Bio
Europe
EMA
pegozafermin
MASH
Madrigal’s Rezdiffra Energizes MASH Space, Sets Bar for Future Therapies
BioSpace
Mon, 03/18/24 - 11:25 am
Madrigal Pharmaceuticals
Rezdiffra
NASH
MASH
Madrigal wins FDA approval of first drug for MASH
BioPharma Dive
Thu, 03/14/24 - 06:27 pm
Madrigal Pharmaceuticals
FDA
Rezdiffra
MASH
NASH

Pages